Fingolimod Provides Long-Term Protection in Rodent Models of Cerebral Ischemia

Creative Commons License

Wei Y., Yemisci M., Kim H., Yung L. M., Shin H. K., Hwang S., ...More

ANNALS OF NEUROLOGY, vol.69, no.1, pp.119-129, 2011 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 69 Issue: 1
  • Publication Date: 2011
  • Doi Number: 10.1002/ana.22186
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.119-129
  • Hacettepe University Affiliated: Yes


Objective: The sphingosine-1-phosphate (S1P) receptor agonist fingolimod (FTY720), that has shown efficacy in advanced multiple sclerosis clinical trials, decreases reperfusion injury in heart, liver, and kidney. We therefore tested the therapeutic effects of fingolimod in several rodent models of focal cerebral ischennia. To assess the translational significance of these findings, we asked whether fingolimod improved long-term behavioral outcomes, whether delayed treatment was still effective, and whether neuroprotection can be obtained in a second species.